ImmunityBio, Inc. IBRX R2K
Healthcare · Biotechnology · United States
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
READ MORE ›$7.52
+182.71% 1Y
Market & Price
Market Cap
$7.88B
Current Price
$7.52
High / Low (52W)
$11.55 / $1.98
Beta
0.07
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
125.33
PEG Ratio
-
Book Value
$-0.83
Price to Book
-9.05
P/S
55.87
EV/EBITDA
-35.13
Dividend Yield
-
Profitability & Returns
ROCE
-54.32%
ROE
-
ROA
-34.38%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.62
EPS (TTM)
$-0.85
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
6.24
Current Ratio
6.67
Debt
$1.12B
Total Assets
$501.90M
Current Assets
$314.88M
Working Capital
$253.12M
Ownership
Promoter Holding
62.48%
Chg in Prom Hold
-
FII / Inst Holding
17.57%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$8.62B
Total Revenue (TTM)
$140.98M
EBITDA
$-245.41M
Free Cash Flow
$-193.70M
Operating Cash Flow
$-294.39M
Shares Outstanding
1.05B
Gross Margin
99.34%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
678.62%
Profit 5Y
5.21%
Revenue (YoY)
167.60%
Earnings (YoY)
-
PROS
- Compounding revenue at 678.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 34.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IBRX ImmunityBio, Inc. R2K | 7.52 | - | $7.88B | - | -54.32% | - | 678.62% | 5.21% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.00K | 82.00K | 40.00K | 1.05M | - | - | 16.52M | 26.43M | 32.06M | 38.28M | 44.21M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 58.00K | 136.00K | 177.00K | 382.00K | 238.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.46M | 26.29M | 31.88M | 37.90M | 43.97M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.89M | 97.57M | 87.51M | 102.59M | 113.76M |
| Operating Income | -46.46M | -29.92M | -31.62M | -34.97M | -32.77M | -25.14M | -25.46M | -23.82M | -24.44M | -25.39M | -28.28M | -28.28M | -24.11M | -17.72M | -18.34M | -17.30M | -16.07M | -16.11M | -36.70M | -50.92M | -65.88M | -30.89M | -86.26M | -85.91M | -78.84M | -95.97M | -79.62M | -90.80M | -111.58M | -85.14M | -80.14M | -95.20M | -99.33M | - | - | -64.43M | -71.28M | -55.63M | -64.68M | -69.79M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -97.21M | -59.54M | -35.77M | -31.04M | -599.94M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.86M | 28.88M | 27.58M | 27.19M | 28.46M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -129.90M | -92.31M | -67.31M | -62.09M | -632.79M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -234.00K | 269.00K | -35.00K | -135.00K | 9.00K |
| Net Income | -46.31M | -26.82M | -30.68M | -34.00M | -31.90M | -24.24M | -24.52M | -23.45M | -23.97M | -24.49M | -27.52M | -27.73M | -23.64M | -17.34M | -17.89M | -16.68M | -15.58M | -15.64M | -37.04M | -51.44M | -65.60M | -32.13M | -79.61M | -88.29M | -87.63M | -102.83M | -94.59M | -110.94M | -116.34M | -137.88M | -95.58M | -134.11M | -134.56M | - | - | -129.65M | -92.56M | -67.25M | -61.94M | -632.78M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.17 | - | -0.21 | -0.23 | -0.22 | -0.26 | -0.24 | -0.28 | -0.27 | -0.32 | -0.19 | -0.20 | -0.20 | - | - | -0.15 | -0.10 | -0.07 | -0.06 | -0.62 |
| R&D Expense | 4.66M | - | 4.96M | 6.39M | 8.36M | - | 9.25M | 9.71M | 11.07M | - | 13.99M | 14.69M | 14.56M | - | 12.60M | 13.13M | 12.05M | - | 27.37M | 33.01M | 35.77M | - | 41.13M | 53.80M | 49.28M | 55.38M | 63.08M | 71.61M | 79.26M | 53.17M | 48.40M | 53.35M | 51.13M | 50.44M | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 240.00K | 622.00K | 14.74M | 113.29M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 753.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | 240.00K | 622.00K | 14.74M | 112.53M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 350.86M | 361.99M | 358.93M | 368.56M |
| Operating Income | - | -5.58M | -238.88M | -124.50M | -99.12M | -98.39M | -156.25M | -220.88M | - | -350.62M | -361.36M | -344.18M | -256.03M |
| EBITDA | - | - | - | - | - | - | - | - | - | -351.88M | -478.58M | -264.35M | -223.56M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 47.15M | 86.80M | 131.74M | 112.53M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -417.29M | -583.89M | -413.64M | -351.61M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 34.00K | -40.00K | 0 | -135.00K |
| Net Income | -2.05M | -6.18M | -236.88M | -120.81M | -96.42M | -96.23M | -157.78M | -221.85M | - | -416.57M | -583.20M | -413.56M | -351.40M |
| Diluted EPS | - | - | - | - | - | - | -0.43 | -0.59 | - | -1.04 | -1.15 | -0.62 | -0.38 |
| R&D Expense | 446.00K | 1.59M | 11.43M | 29.15M | 42.04M | 55.72M | 112.00M | 139.51M | 195.96M | 248.15M | 232.37M | 190.14M | - |
Compounded Sales Growth
| 5 Years: | 678.62% |
| 1 Year: | 167.60% |
Compounded Profit Growth
| 5 Years: | 5.21% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +182.71% |
| 6 Months: | +261.54% |
| 3 Months: | -23.11% |
| 1 Month: | +8.05% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 366.85M | 317.50M | 250.44M | 181.95M | 143.12M | 221.38M | - | 362.36M | 504.45M | 382.93M | 501.90M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 140.58M | 294.08M | 184.59M | 314.88M |
| Cash & Equivalents | 116.00K | 350.00K | 59.10M | 175.91M | 8.08M | 23.87M | 16.82M | 75.80M | 34.91M | - | 104.64M | 265.45M | 143.43M | 88.33M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 0 | 8.27M | 910.00K |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 0 | 2.36M | 42.57M |
| Total Liabilities | - | - | - | 10.85M | 24.08M | 31.60M | 35.94M | 22.44M | 339.87M | - | 812.18M | 1.09B | 871.06M | 1.00B |
| Current Liabilities | - | - | 1.88M | 6.15M | 12.55M | 20.87M | 27.26M | 11.56M | 68.13M | - | 500.86M | 58.28M | 54.94M | 61.75M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 241.27M | 681.54M | 461.88M | 477.09M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 723.77M | 726.72M | 504.17M | 518.08M |
| Total Equity | - | -3.75M | 57.59M | 356.00M | 293.42M | 218.84M | 146.01M | 120.68M | -119.81M | - | -447.33M | -586.99M | -489.10M | -500.47M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 421.73M | 671.03M | 853.07M | 1.01B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -38.59M | -48.78M | -63.38M | -152.11M | -171.72M | - | -337.51M | -366.76M | -391.24M | -304.94M |
| Investing Cash Flow | - | - | - | -113.67M | 99.55M | 57.10M | 18.55M | -19.81M | - | 27.30M | -30.47M | -12.25M | -149.80M |
| Financing Cash Flow | - | - | - | -15.56M | -34.98M | -771.00K | 114.28M | 150.68M | - | 233.61M | 558.34M | 281.63M | 400.24M |
| Capital Expenditure | -3.00K | -235.00K | -2.24M | -6.56M | -34.81M | -13.10M | -4.29M | -1.67M | - | -99.39M | -30.58M | -6.89M | -4.25M |
| Free Cash Flow | - | - | - | -45.15M | -83.59M | -76.48M | -156.40M | -173.39M | - | -436.90M | -397.34M | -398.12M | -309.19M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -76.60M | 161.11M | -121.85M | -54.50M |
| Share Buybacks | - | 0 | 4.80M | 15.85M | 15.23M | 228.00K | 2.50M | 0 | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 100.0% | 100.0% | 100.0% | 99.3% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | -146,090.4% | -58,097.1% | -2,334.2% | -226.0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | -173,569.6% | -93,761.4% | -2,804.8% | -310.2% |
| ROE % | 54.5% | -10.7% | -66.5% | -41.2% | -44.1% | -65.9% | -130.7% | 185.2% | - | 93.1% | 99.4% | 84.6% | 70.2% |
| ROCE % | - | - | -66.2% | -40.8% | -43.2% | -63.6% | -118.8% | -144.1% | - | 253.1% | -81.0% | -104.9% | -58.2% |
Shareholding Pattern
Insiders
62.48%
Institutions
17.57%
Public Float
46.82%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 2.52% | 26.35M | $198.13M |
| 2 | State Street Corporation | 1.69% | 17.71M | $133.16M |
| 3 | Vanguard Portfolio Management LLC | 1.56% | 16.32M | $122.75M |
| 4 | Vanguard Capital Management LLC | 1.44% | 15.13M | $113.76M |
| 5 | Shaw D.E. & Co., Inc. | 1.20% | 12.57M | $94.54M |
| 6 | Geode Capital Management, LLC | 0.77% | 8.03M | $60.40M |
| 7 | Two Sigma Investments, LP | 0.42% | 4.39M | $32.98M |
| 8 | Morgan Stanley | 0.38% | 4.02M | $30.22M |
| 9 | HRT Financial LP | 0.37% | 3.93M | $29.52M |
| 10 | Woodline Partners LP | 0.33% | 3.45M | $25.92M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IBRX
No recent headlines available.